Loading stock data…
TFC
$49.76-1.17 (-2.31%)
Market OpenUpdated 11:49 AM EDT
Truist Financial Corporation, a financial services company, provides banking and trust services in the Southeastern and Mid-Atlantic United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Truist Financial Corporation in the Financial Services sector is trading at $50.93. The stock is currently 9% below its 52-week high of $56.20, remaining 9.2% above its 200-day moving average. Technical signals show neutral RSI of 58 and bullish MACD crossover, explaining why TFC maintains its current momentum and trend strength. The Whystock Score of 70/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 58) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JPMBACGS
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$49.76
Potential Upside
55.4%
Whystock Fair Value$77.33
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus19 analysts
Buy
Mean target$55.53+11.6%
Range$45.00 – $63.00
Fundamentals
Truist Financial Corporation, a financial services company, provides banking and trust services in the Southeastern and Mid-Atlantic United States. The company operates through two segments, Consumer and Small Business Banking; and Wholesale Banking....
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$63.48B
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
12.61
Beta
Defensive asset. Lower volatility than the S&P 500.
0.87
Div Yield
Strong income play. Yield provides a meaningful total return floor.
408.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
8.01%
Volume
Today's trading volume
1.91M
Recent News
Truist Financial AGM: Shareholders Back Directors, Pay, PwC as CEO Rogers Reaffirms ROTCE Targets
Truist Financial (NYSE:TFC) held its 2026 annual meeting of shareholders virtually, with Chief Legal Officer and Corporate Secretary Scott Stengel opening the session and noting that meeting materials—including the proxy statement, annual report, Form 10-K, and rules of conduct—were available online
How The UDR (UDR) Investment Story Is Shifting With New Guidance And Analyst Rethinks
UDR’s fair value estimate has been nudged to US$40.48 from US$40.52, a shift of roughly 0.1% that keeps the stock’s modeled worth firmly around the US$40 mark. That small adjustment sits alongside a flurry of Street price target moves clustered in the high US$30s to low US$40s, reflecting different views on how earnings, capital allocation, and multifamily trends could develop. Read on to see how this evolving analyst narrative can help you track what matters most for UDR’s valuation...
How Dividend Declaration And Truist Downgrade At Tronox (TROX) Has Changed Its Investment Story
In late April 2026, Tronox Holdings plc declared a quarterly dividend of US$0.0500 per share, payable on July 8, 2026, to shareholders of record as of the May 11 ex-dividend date. Around the same time, Truist cut its rating on Tronox to Sell, pointing to cost pressures and geographic mix risks that could weigh on near-term earnings and cash flows. Against this backdrop, we’ll examine how Truist’s downgrade, focused on cost and earnings risks, may alter Tronox’s investment narrative. We've...
How The PROCEPT BioRobotics (PRCT) Investment Story Is Shifting After Q4 Miss And Guidance Reset
PROCEPT BioRobotics’ model fair value sits at US$30.44 per share, with no change to the central price target despite refreshed assumptions. That steady target comes as analysts split between focusing on long term Aquablation adoption potential and near term execution risks following the Q4 miss and guidance reset. In the following sections, you will see how these updates fit into the broader analyst narrative and what to watch as views on the stock continue to evolve. Analyst Price Targets...
How The Story Is Shifting For Monolithic Power Systems (MPWR) As Price Targets Reset
The latest update lifts Monolithic Power Systems’ fair value estimate from US$1,328.29 to US$1,417.57, adjusting the price target that many investors watch closely. That shift sits alongside a series of higher Street targets, including multiple triple digit increases. Together, these moves indicate how analysts are recalibrating their views on potential upside and execution risk. As you read on, you will see how these target moves fit into the broader narrative and how to keep track as it...